Fortitude Family Office’s Larimar Therapeutics LRMR Stock Holding History

Fortitude Family Office’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.02K	Sell	319 -63	-16%	-$244	﹤0.01%	2238
2026 Q2	$1.17K	Buy	382 +234	+158%	+$929	﹤0.01%	1695
2026 Q1	$666	Buy	+148	New	+$592	﹤0.01%	1623

Other funds holding LRMR

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Fortitude Family Office's LRMR Position: Q3 2026 in Review

Fortitude Family Office reduced its Larimar Therapeutics (LRMR) stake by 16% in Q3 2026, selling an estimated $244 and leaving 319 shares worth $1.02K. The position accounts for ﹤0.01% of the portfolio, ranked #2238.

Fortitude Family Office first reported a position in LRMR in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.17K in Q2 2026. 7 funds tracked by Wall St. Rank hold LRMR as of Q3 2026.

Fortitude Family Office held 319 shares of Larimar Therapeutics worth $1.02K as of Q3 2026.
Fortitude Family Office sold 63 Larimar Therapeutics shares in Q3 2026, an estimated $244.
Larimar Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #2238 holding.
Fortitude Family Office first reported a position in Larimar Therapeutics in Q1 2026 and has held it in 3 quarters since.
Fortitude Family Office's Larimar Therapeutics position peaked at $1.17K in Q2 2026.
7 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.